Know Cancer

or
forgot password

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer


N/A
14 Years
85 Years
Open (Enrolling)
Both
Metastatic Colorectal Cancer

Thank you

Trial Information

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer


A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with
Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer


Inclusion Criteria:



- Patients with diagnosed Metastatic Colorectal Cancer

Exclusion Criteria:

- Patients with diagnosis other than Metastatic Colorectal Cancer

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Shouki Bazarbashi, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

KFSH & RC

Authority:

United States: Institutional Review Board

Study ID:

RAC# 2081-068

NCT ID:

NCT01311050

Start Date:

January 2009

Completion Date:

Related Keywords:

  • Metastatic Colorectal Cancer
  • Metastatic Colorectal Cancer
  • Colorectal Neoplasms

Name

Location